A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review

11Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

BNT162b2 (Pfizer/BioNTech) is a coronavirus disease 2019 (COVID-19) vaccine containing nucleoside-modified messenger RNA encoding the severe acute respiratory syndrome coronavirus 2 spike glycoprotein. Recently, ocular complications of mRNA vaccines have been reported increasingly frequently. However, immunological adverse events due to mRNA vaccines in real-world settings are not fully known. We herein report the novel development of sarcoidosis manifested as uveitis, bilateral hilar lymphadenopathy, angiotensin-converting enzyme elevation, and epithelioid and giant cell granuloma formation in the lung soon after the first BNT162b2 injection and review the current literature, including three reported cases of sarcoid-like reaction following COVID-19 vaccination.

Cite

CITATION STYLE

APA

Numakura, T., Murakami, K., Tamada, T., Yamaguchi, C., Inoue, C., Ohkouchi, S., … Sugiura, H. (2022). A Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review. Internal Medicine. Japanese Society of Internal Medicine. https://doi.org/10.2169/internalmedicine.0104-22

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free